Company Profile
3D MEDICINES
Description
3D Medicines Inc., a biopharmaceutical company, researches, develops, and commercializes oncology products and other drug candidates for the treatment of patients with various cancers in the Mainland China. The company offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors. It is also developing Envafolimab, which is in Phase III clinical trials for advanced BTC and NSCLC; and in Phase II clinical trials G/GEJ and TMB-H advanced cancer, EC, HCC,CRC, NSCLC, microsatellite satble CRC, and dMMR advanced sold tumors. In addition, it provides products which is in development pipeline include 3D189 for multi-indication tumor and is in phase III clinical trial; 3D229 (GAS6/AXL) for non-small cell lung cancer, ovarian cancer, and kidney cancer and is in phase III clinical trial; 3D1001 for the treatment of postoperative dental pain and tumor pain which is in phase II trial; 3D1002 for cancer pain/osteoarthritis and is in phase II trial; and 3D185, which is in phase I clinical trial for the treatment of locally advanced or metastatic solid tumors, as well as other products, such as 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumor; and 3D057, 3D124, 3D060, and 3D062 for multiple indications tumors. 3D Medcines Inc. was founded in 2014 and is headquartered in Qingdao, China.
Reports
This company has 1 ESG reports available.
ESG Performance Overview
Select a KPI indicator to view performance trend
KPI Indicators
A1.2 Direct (Scope 1) and Indirect (Scope 2) GHG Emissions
12 Data Points| Indicator | Data Points | Actions |
|---|---|---|
| Total GHG Emissions Intensity (By Revenue) | 3 | |
| Total GHG Emissions | 3 | |
| Direct GHG Emissions (Scope 1) | 3 | |
| Indirect Energy Emissions (Scope 2) | 3 |
A1.3 Hazardous Waste
6 Data Points| Indicator | Data Points | Actions |
|---|---|---|
| Total Hazardous Waste Intensity (By Revenue) | 3 | |
| Total Hazardous Waste | 3 |
A2.1 Energy Consumption
9 Data Points| Indicator | Data Points | Actions |
|---|---|---|
| Total Indirect Energy Consumption | 3 | |
| Purchased Electricity | 3 | |
| Grid Electricity Consumption | 3 |
A2.2 Water Consumption
12 Data Points| Indicator | Data Points | Actions |
|---|---|---|
| Total Water Withdrawal | 3 | |
| Water Consumption | 3 | |
| Municipal Water Consumption | 3 | |
| Water Consumption Intensity (By Revenue) | 3 |
A2.3 Energy Use Efficiency Targets
4 Data Points| Indicator | Data Points | Actions |
|---|---|---|
| Energy Consumption Reduction Compared to Last Year | 2 | |
| Energy Consumption Reduction Percentage Compared to Last Year | 2 |
B1.1 Amount and Distribution of Workforce
7 Data Points| Indicator | Data Points | Actions |
|---|---|---|
| Number of Total Employees | 1 | |
| Percentage of Male Employees | 1 | |
| Percentage of Female Employees | 1 | |
| Number of Full-time Employees | 1 | |
| Percentage of Employees Aged Below 30 | 1 | |
| Percentage of Employees Aged 30-50 | 1 | |
| Percentage of Employees Aged Above 50 | 1 |
B1.2 Employee Turnover Rate
5 Data Points| Indicator | Data Points | Actions |
|---|---|---|
| Turnover Rate of Female Employees | 1 | |
| Turnover Rate of Employees Aged Below 30 | 1 | |
| Turnover Rate of Employees Aged 30-50 | 1 | |
| Turnover Rate of Employees Aged Above 50 | 1 | |
| Turnover Rate of Total Employees | 1 |
B2.1 Number and Rate of Work-related Fatalities
2 Data Points| Indicator | Data Points | Actions |
|---|---|---|
| Number of Work-related Fatalities | 1 | |
| Number of Fatalities as a Result of Work-related Injuries | 1 |
B2.2 Lost Days Due to Work Injury
1 Data Points| Indicator | Data Points | Actions |
|---|---|---|
| Lost Days Due to Work-related Injuries | 1 |
B3.1 The Percentage of Employees Trained
1 Data Points| Indicator | Data Points | Actions |
|---|---|---|
| Percentage of Employees Trained | 1 |
B3.2 Average Training Hours Completed per Employee
2 Data Points| Indicator | Data Points | Actions |
|---|---|---|
| Total Training Hours | 1 | |
| Average Training Hours per Employee | 1 |
B5.1 Number of Suppliers by Geographical Region
3 Data Points| Indicator | Data Points | Actions |
|---|---|---|
| Number of Total Suppliers | 1 | |
| Number of Suppliers in Mainland China | 1 | |
| Number of Suppliers in Overseas | 1 |
B6.3 Protection on Intellectual Property Rights
5 Data Points| Indicator | Data Points | Actions |
|---|---|---|
| Number of Intellectual Property Rights Obtained by the Company | 1 | |
| Number of Patents Granted | 1 | |
| Number of Patents Held | 1 | |
| Number of New Patent Applications | 1 | |
| Number of Trademark Registrations | 1 |
B7.3 Anti-corruption Training
1 Data Points| Indicator | Data Points | Actions |
|---|---|---|
| Number of Anti-corruption Training Session | 1 |
ESG Reports
| Year | Report Title | Publication Date | Raw KPIs | Standard KPIs | Processed | Actions |
|---|---|---|---|---|---|---|
| 2023 | Environmental, Social and Governance Report 2023 | 2024-04-28 | 100 | 70 | Yes |